

Drug 1	Drug 2	Drug 3	Disease	Phase	Number of Subjects	Drug 1 Dose Percent	Drug 2 Dose Percent	Drug 3 Dose Percent
AEG35156	cytarabine	idarubicin	acute myeloid leukemia	2	27	69%	100%	100%
afatinib	5-fluorouracil	cisplatin	advanced solid tumors	1	47	75%	100%	47%
afatinib	cisplatin	paclitaxel	advanced solid tumors	1	47	50%	100%	100%
aflibercept	5-fluorouracil	irinotecan	advanced solid tumor	1	27	100%	100%	100%
aflibercept	5-fluorouracil	irinotecan	colorectal cancer	3	604	100%	100%	100%
aflibercept	5-fluorouracil	irinotecan	colorectal cancer	1	16	100%	100%	90%
aflibercept	5-fluorouracil	irinotecan	solid tumors	1	38	100%	100%	100%
aflibercept	5-fluorouracil	irinotecan	metastatic colorectal cancer	3	604	100%	100%	100%
aflibercept	cisplatin	docetaxel	solid tumors	1	30	100%	100%	100%
aflibercept	cisplatin	pemetrexed	non-small cell lung cancer	2	42	100%	100%	100%
aflibercept	cisplatin	pemetrexed	advanced solid tumors	1	18	100%	100%	100%
alemtuzumab	cytoxan	fludarabine	chronic lymphocytic leukemia	2	43	17%	60%	69%
alemtuzumab	cytoxan	fludarabine	chronic lymphocytic leukemia	3	80	25%	96%	80%
AT-101	cisplatin	etoposide	advanced solid tumors	1	20	76%	80%	40%
AVE1642	erlotinib	gemcitabine	advanced solid tumors	1	10	33%	50%	50%
axitinib	5-fluorouracil	oxaliplatin	colorectal cancer	2	39	100%	100%	100%
axitinib	5-fluorouracil	oxaliplatin or irinotecan	solid tumors	1	14	100%	100%	100%
axitinib	carboplatin	paclitaxel	solid tumors	1	28	100%	100%	100%
axitinib	cisplatin	gemcitabine	solid tumors	1	21	100%	100%	80%
belinostat	carboplatin	paclitaxel	advanced solid tumors	1	23	100%	100%	57%
belinostat	carboplatin	paclitaxel	ovarian cancer	2	35	100%	100%	100%
bevacizumab	5-fluorouracil	cetuximab	colorectal cancer	3	121	50%	100%	100%
bevacizumab	5-fluorouracil	cisplatin	advanced esophageal cancer	2	28	50%	47%	100%
bevacizumab	5-fluorouracil	enzastaurin	metastatic colorectal cancer	2	58	50%	95%	100%
bevacizumab	5-fluorouracil	gemcitabine	metastatic colorectal cancer	2	18	50%	64%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	72	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	25	100%	100%	90%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	167	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	3	142	50%	63%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	43	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	37	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	advanced colorectal cancer	2	47	50%	90%	100%

bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	39	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	3	131	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	30	50%	90%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	61	50%	100%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	34	50%	90%	100%
bevacizumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	55	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	advanced colorectal cancer	3	713	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	colon cancer	3	1155	50%	94%	98%
bevacizumab	5-fluorouracil	oxaliplatin	colon cancer	3	1354	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	colorectal cancer	3	118	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colon cancer	2	21	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	18	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	50	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	3	66	100%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	43	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	64	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colon cancer	2	86	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	advanced colorectal cancer	2	47	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	colorectal cancer	3	255	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	3	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	48	50%	100%	100%
bevacizumab	5-fluorouracil	oxaliplatin	colorectal cancer	2	68	50%	100%	100%
bevacizumab	capecitabine	cisplatin	gastric cancer	3	387	50%	100%	80%
bevacizumab	capecitabine	docetaxel	HER2 negative breast cancer	2	45	100%	100%	66%
bevacizumab	capecitabine	docetaxel	metastatic breast cancer	2	45	100%	100%	66%
bevacizumab	capecitabine	gemcitabine	metastatic renal cell carcinoma	2	29	100%	45%	100%
bevacizumab	capecitabine	irinotecan	metastatic colorectal cancer	2	71	50%	80%	80%
bevacizumab	capecitabine	irinotecan	metastatic colorectal cancer	2	166	50%	80%	100%
bevacizumab	capecitabine	irinotecan	metastatic colorectal cancer	2	50	50%	80%	80%
bevacizumab	capecitabine	irinotecan	metastatic colorectal cancer	2	46	50%	100%	60%
bevacizumab	capecitabine	irinotecan	metastatic colorectal cancer	3	134	50%	96%	40%
bevacizumab	capecitabine	mitomycin	metastatic colorectal cancer	3	158	100%	100%	35%
bevacizumab	capecitabine	oxaliplatin	advanced colorectal cancer	1 and 2	39	50%	90%	100%
bevacizumab	capecitabine	oxaliplatin	advanced hepatocellular carcinoma	2	40	33%	66%	100%

bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	3	123	50%	80%	100%
bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	2	50	100%	73%	100%
bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	3	480	50%	80%	100%
bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	2	46	50%	68%	100%
bevacizumab	capecitabine	oxaliplatin	rectal cancer	2	32	50%	80%	100%
bevacizumab	capecitabine	oxaliplatin	colon cancer	3	1145	50%	100%	86%
bevacizumab	capecitabine	oxaliplatin	esophageal adenocarcinoma	2	35	100%	100%	68%
bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	1 and 2	58	50%	100%	80%
bevacizumab	capecitabine	oxaliplatin	rectal cancer	2	49	50%	100%	80%
bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	2	211	50%	90%	100%
bevacizumab	capecitabine	oxaliplatin	metastatic colorectal cancer	2	208	50%	68%	100%
bevacizumab	capecitabine	trastuzumab	HER2 positive breast cancer	2	88	100%	100%	80%
bevacizumab	carboplatin	docetaxel	non-small cell lung cancer	2	40	100%	100%	100%
bevacizumab	carboplatin	etoposide	small cell lung cancer	2	26	100%	100%	100%
bevacizumab	carboplatin	gemcitabine	epithelial ovarian, peritoneal, or fallopian tube cancer	3	241	100%	100%	100%
bevacizumab	carboplatin	gemcitabine	non-squamous non-small cell lung cancer	2	48	100%	100%	100%
bevacizumab	carboplatin	gemcitabine	metastatic urothelial cancer	2	51	100%	100%	100%
bevacizumab	carboplatin	irinotecan	recurrent glioblastoma	2	40	100%	100%	75%
bevacizumab	carboplatin	ixabepilone	advanced non-small cell lung cancer	2	40	100%	100%	75%
bevacizumab	carboplatin	liposomal doxorubicin	ovarian, fallopian tube, or primary peritoneal cancer	2	54	100%	100%	89%
bevacizumab	carboplatin	nab-paclitaxel	metastatic melanoma	2	51	100%	100%	64%
bevacizumab	carboplatin	nab-paclitaxel	triple negative metastatic breast cancer	2	34	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	advanced mullerian tumors	2	62	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	advanced non-squamous non-small cell lung cancer	2	119	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	melanoma	2	143	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	non-small cell lung cancer	2	48	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	non-squamous non-small-cell lung cancer	3	443	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	non-small cell lung cancer	2	23	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	non-small cell lung cancer	2	26	100%	100%	100%

bevacizumab	carboplatin	paclitaxel	non-squamous non-small cell lung cancer	2	63	100%	100%	100%
bevacizumab	carboplatin	paclitaxel	ovarian cancer	2	189	50%	100%	100%
bevacizumab	carboplatin	pemetrexed	malignant pleural mesothelioma	2	76	100%	100%	100%
bevacizumab	carboplatin	pemetrexed	non-small cell lung cancer	2	20	100%	100%	100%
bevacizumab	carboplatin	pemetrexed	non-squamous non-small-cell lung cancer	3	442	100%	100%	100%
bevacizumab	carboplatin	pemetrexed	non-squamous non-small cell lung cancer	2	40	100%	100%	100%
bevacizumab	carboplatin	S-1	advanced nonsquamous non-small cell lung cancer	2	48	100%	100%	100%
bevacizumab	carboplatin	docetaxel	triple-negative breast cancer	2	45	100%	100%	100%
bevacizumab	cisplatin	docetaxel	non-squamous non-small cell lung cancer	2	48	100%	100%	100%
bevacizumab	cisplatin	docetaxel	resectable non-squamous non-small cell lung cancers	2	50	100%	100%	100%
bevacizumab	cisplatin	docetaxel	metastatic breast cancer	2	20	50%	100%	100%
bevacizumab	cisplatin	etoposide	advanced non-small cell lung cancer	1 and 2	48	50%	100%	50%
bevacizumab	cisplatin	etoposide	small cell lung cancer	2	26	100%	100%	100%
bevacizumab	cisplatin	gemcitabine	malignant mesothelioma	2	53	100%	100%	100%
bevacizumab	cisplatin	gemcitabine	metastatic urothelial cell carcinoma	2	43	100%	93%	100%
bevacizumab	cisplatin	irinotecan	extensive-stage small cell lung cancer	2	64	100%	80%	52%
bevacizumab	cisplatin	pemetrexed	malignant mesothelioma	2	52	100%	100%	94%
bevacizumab	cisplatin	S-1	non-small cell lung cancer	2	30	100%	80%	100%
bevacizumab	cisplatin	topotecan	cervical cancer	2	27	100%	67%	30%
bevacizumab	cisplatin	vinorelbine	advanced non-squamous non-small cell lung cancer	2	49	100%	100%	67%
bevacizumab	cytoxan	doxorubicin	breast cancer	2	78	100%	100%	86%
bevacizumab	cytoxan	doxorubicin	HER2 positive breast cancer	2	45	100%	100%	86%
bevacizumab	docetaxel	epirubicin	HER2 negative metastatic breast cancer	1 and 2	83	100%	100%	100%
bevacizumab	docetaxel	estramustine	prostate cancer	2	77	100%	100%	29%

bevacizumab	docetaxel	gemcitabine	soft tissue sarcoma	1	36	50%	100%	100%
bevacizumab	docetaxel	oxaliplatin	metastatic gastric and gastroesophageal junction cancers	2	38	50%	100%	58%
bevacizumab	docetaxel	oxaliplatin	non-small cell lung cancer	2	53	100%	100%	77%
bevacizumab	docetaxel	thalidomide	metastatic castrate resistant prostate cancer	2	60	100%	100%	100%
bevacizumab	docetaxel	trastuzumab	metastatic breast cancer	2	20	100%	100%	100%
bevacizumab	everolimus	panitumumab	advanced solid tumors	1	32	100%	80%	21%
bevacizumab	everolimus	panobinostat	advanced solid tumors	1	12	100%	50%	33%
bevacizumab	gemcitabine	nab-paclitaxel	HER2 negative metastatic breast cancer	2	29	100%	100%	80%
bevacizumab	gemcitabine	oxaliplatin	advanced biliary tract cancers	2	35	100%	83%	100%
bevacizumab	gemcitabine	oxaliplatin	advanced pancreatic cancer	2	50	100%	83%	100%
bevacizumab	gemcitabine	oxaliplatin	advanced pancreatic cancer	2	19	100%	100%	100%
bevacizumab	gemcitabine	paclitaxel	metastatic breast cancer	2	93	100%	100%	100%
bevacizumab	irinotecan	S-1	metastatic colon cancer	2	38	56%	38%	90%
bevacizumab	irinotecan	S-1	colorectal cancer	2	52	40%	63%	60%
bevacizumab	irinotecan	S-1	metastatic colorectal cancer	2	30	50%	60%	100%
bevacizumab	irinotecan	vorinostat	glioblastoma multiforme	1	19	100%	50%	50%
bevacizumab	liposomal doxorubicin	temsirolimus	advanced gynecologic/breast malignancies	1	7	100%	100%	100%
bevacizumab	liposomal doxorubicin	temsirolimus	advanced malignancies	1	136	100%	100%	100%
bevacizumab	oxaliplatin	S-1	advanced solid tumors	1	24	50%	100%	66%
bevacizumab	oxaliplatin	S-1	advanced solid tumors	1	24	50%	100%	63%
bevacizumab	oxaliplatin	S-1	colorectal cancer	3	256	50%	100%	100%
bevacizumab	paclitaxel	sorafenib	advanced/metastatic solid tumors	1	21	100%	50%	100%
bevacizumab	paclitaxel	vorinostat	metastatic breast cancer	1 and 2	53	100%	48%	100%
bexarotene	carboplatin	paclitaxel	non-small cell lung cancer	1	22	100%	100%	100%
bexarotene	cisplatin	vinorelbine	advanced non-small cell lung cancer	1	26	100%	100%	100%
bortezomib	bendamustine	rituximab	relapsed or refractory follicular lymphoma	2	73	92%	100%	90%

bortezomib	bendamustine	rituximab	relapsed/refractory, indolent, and mantle cell non-Hodgkin's lymphoma	2	30	75%	25%	90%
bortezomib	carboplatin	paclitaxel	metastatic malignant melanoma	2	17	75%	100%	100%
bortezomib	gemcitabine	liposomal doxorubicin	advanced malignancies	1	28	100%	89%	100%
bortezomib	liposomal doxorubicin	thalidomide	multiple myeloma	2	43	75%	100%	100%
cediranib	5-fluorouracil	oxaliplatin	advanced colorectal cancer	3	709	44%	100%	100%
cediranib	5-fluorouracil	oxaliplatin	advanced solid tumors	1	14	67%	100%	100%
cediranib	5-fluorouracil	oxaliplatin	colon cancer	1	13	67%	100%	100%
cediranib	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	114	44%	100%	100%
cediranib	capecitabine	cisplatin	advanced gastric cancer	1	6	44%	100%	80%
cediranib	carboplatin	gemcitabine	non-small cell lung cancer	2	91	67%	100%	100%
cediranib	carboplatin	paclitaxel	advanced non-small cell lung cancer	2	126	100%	100%	100%
cediranib	carboplatin	paclitaxel	advanced non-small cell lung cancer	3	151	67%	100%	100%
cediranib	cetuximab	irinotecan	advanced solid tumors	1	5	67%	100%	100%
cediranib	cisplatin	S-1	advanced gastric cancer	1	8	44%	48%	45%
cediranib	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	3	144	100%	100%	100%
cetuximab	5-fluorouracil	cisplatin	recurrent and/or metastatic squamous cell carcinoma of the head and neck	2	33	100%	100%	100%
cetuximab	5-fluorouracil	irinotecan	advanced gastroesophageal cancer	2	49	100%	100%	82%
cetuximab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	55	100%	100%	100%
cetuximab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	74	100%	100%	100%
cetuximab	5-fluorouracil	irinotecan	colon cancer	3	40	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	advanced colorectal cancer	2	82	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	colorectal cancer	3	407	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	56	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	82	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	77	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	3	372	100%	94%	100%

cetuximab	5-fluorouracil	oxaliplatin	KRAS wild-type metastatic colorectal cancer	2	80	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	KRAS wild-type metastatic colorectal cancer	2	81	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	150	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	72	100%	100%	100%
cetuximab	5-fluorouracil	oxaliplatin	metastatic head and neck cancer	1	10	100%	77%	100%
cetuximab	bevacizumab	gemcitabine	pancreatic cancer	2	30	100%	100%	100%
cetuximab	bevacizumab	irinotecan	glioblastoma multiforme	2	43	100%	100%	75%
cetuximab	capecitabine	cisplatin	advanced gastric cancer	3	447	100%	100%	80%
cetuximab	capecitabine	everolimus	advanced pancreatic cancer	1 and 2	46	100%	50%	48%
cetuximab	capecitabine	gemcitabine	biliary tract cancer	2	34	100%	100%	52%
cetuximab	capecitabine	irinotecan	metastatic colorectal cancer	2	89	100%	64%	80%
cetuximab	capecitabine	oxaliplatin	metastatic colorectal cancer	2	12	100%	68%	100%
cetuximab	capecitabine	oxaliplatin	metastatic colorectal cancer	2	88	100%	64%	100%
cetuximab	capecitabine	oxaliplatin	metastatic or recurrent advanced gastric cancer	2	44	100%	80%	100%
cetuximab	capecitabine	oxaliplatin	colorectal cancer	3	408	100%	100%	68%
cetuximab	capecitabine	oxaliplatin	hepatocellular carcinoma	2	29	100%	100%	68%
cetuximab	carboplatin	docetaxel	locally advanced or metastatic non-small cell lung cancer	2	74	100%	100%	100%
cetuximab	carboplatin	paclitaxel	advanced stage non-small cell lung cancer	2	106	100%	100%	100%
cetuximab	carboplatin	paclitaxel or docetaxel	advanced non-small cell lung cancer	3	338	100%	100%	100%
cetuximab	cisplatin	pemetrexed	advanced non-squamous non-small cell lung cancer	2	113	100%	100%	100%
cetuximab	cisplatin	pemetrexed	squamous cell carcinoma of the head and neck	2	66	100%	100%	100%
cetuximab	docetaxel	gemcitabine	non-small cell lung cancer	2	69	100%	100%	100%
cetuximab	docetaxel	oxaliplatin	metastatic gastric or gastroesophageal junction adenocarcinoma	2	75	100%	100%	100%
cetuximab	gemcitabine	oxaliplatin	advanced pancreatic cancer	2	41	100%	100%	67%

cetuximab	gemcitabine	oxaliplatin	metastatic biliary tract cancer	2	30	100%	100%	67%
cetuximab	irinotecan	oxaliplatin	advanced gastric cancer	2	51	100%	75%	100%
cetuximab	irinotecan	sorafenib	advanced colorectal cancer	1	18	100%	100%	80%
cetuximab	irinotecan	vandetanib	metastatic colorectal cancer	1	27	100%	67%	93%
cetuximab	oxaliplatin	tegafur-uracil	metastatic colorectal cancer	2	151	100%	100%	83%
CKD-732	capecitabine	oxaliplatin	metastatic colorectal cancer	1	9	33%	100%	80%
conatumumab	5-fluorouracil	irinotecan	KRAS mutant metastatic colorectal cancer	2	50	50%	100%	100%
conatumumab	carboplatin	paclitaxel	advanced non-small cell lung cancer	2	109	50%	100%	100%
CP-868,596	axitinib	docetaxel	advanced solid tumors	1	9	60%	100%	100%
CP-870,893	carboplatin	paclitaxel	advanced solid tumors	1	32	100%	100%	100%
custirsen	carboplatin	gemcitabine	non-small cell lung cancer	1 and 2	15	67%	100%	100%
custirsen	cisplatin	gemcitabine	non-small cell lung cancer	1 and 2	60	67%	100%	100%
dalotuzumab	cetuximab	irinotecan	colorectal cancer	1	20	100%	100%	90%
enzastaurin	carboplatin	paclitaxel	ovarian cancer	2	69	95%	100%	100%
enzastaurin	carboplatin	pemetrexed	non-small cell lung cancer	2	72	95%	100%	100%
enzastaurin	cisplatin	pemetrexed	non-small cell lung cancer	2	35	95%	100%	100%
erlotinib	5-fluorouracil	oxaliplatin	metastatic or advanced adenocarcinoma of the esophagus and gastro-esophageal junction	2	33	100%	100%	100%
erlotinib	bevacizumab	cetuximab	non-small cell lung cancer	1	34	100%	100%	100%
erlotinib	capecitabine	gemcitabine	pancreatic cancer	2	47	67%	100%	75%
erlotinib	capecitabine	gemcitabine	advanced pancreatic cancer	1	16	83%	75%	100%
erlotinib	carboplatin	gemcitabine	non-small cell lung cancer	3	205	50%	100%	100%
erlotinib	carboplatin	paclitaxel	lung adenocarcinoma	2	100	100%	100%	100%
erlotinib	carboplatin	paclitaxel	ovarian cancer	2	56	100%	100%	100%
erlotinib	carboplatin	paclitaxel	non-small cell lung cancer	3	209	100%	100%	100%
erlotinib	cisplatin	gemcitabine	non-small cell lung cancer	3	17	50%	75%	100%
erlotinib	cisplatin	gemcitabine	advanced pancreatic cancer	2	22	67%	100%	67%
everolimus	carboplatin	paclitaxel	metastatic melanoma	2	70	50%	100%	100%
everolimus	cisplatin	docetaxel	head and neck cancer	1	15	75%	100%	100%
everolimus	cisplatin	etoposide	small cell lung cancer	1	40	25%	100%	100%
everolimus	cytarabine	daunorubicin	acute myeloid leukemia	1	28	50%	100%	100%



everolimus	paclitaxel	trastuzumab	HER2 positive breast cancer	2	55	100%	100%	100%
everolimus	paclitaxel	trastuzumab	metastatic breast cancer	1	33	100%	100%	100%
figitumumab	carboplatin	paclitaxel	advanced non-small cell lung cancer	1	18	100%	100%	100%
flavopiridol	5-fluorouracil	irinotecan	advanced solid tumors	1	63	100%	100%	100%
flavopiridol	gemcitabine	irinotecan	advanced solid tumors	1	14	100%	100%	48%
ganitumab	5-fluorouracil	irinotecan	KRAS mutant metastatic colorectal cancer	2	51	50%	100%	100%
gefitinib	carboplatin	paclitaxel	ovarian, tubal, or peritoneal adenocarcinoma	2	68	100%	100%	100%
gefitinib	cytoxan	epirubicin	estrogen receptor negative early breast cancer	2	94	100%	100%	86%
gefitinib	irinotecan	paclitaxel	non-small cell lung cancer	2	16	33%	91%	24%
gemtuzumab ozogamicin	cytarabine	daunorubicin	acute myeloid leukemia	1	10	33%	100%	100%
gemtuzumab ozogamicin	cytarabine	daunorubicin	acute myeloid leukemia	3	295	33%	100%	100%
gemtuzumab ozogamicin	cytarabine	daunorubicin	acute myeloid leukemia	1 and 2	20	50%	100%	100%
gemtuzumab ozogamicin	cytarabine	idarubicin	acute myeloid leukemia	1	9	33%	100%	100%
imatinib	bevacizumab	cytoxan	advanced colorectal cancer	1	35	50%	50%	70%
imatinib	cisplatin	pemetrexed	pleural mesothelioma	1	17	100%	75%	75%
imatinib	cytarabine	daunorubicin	c-kit positive acute myeloid leukemia	1	21	75%	100%	100%
imatinib	docetaxel	gemcitabine	refractory/relapsed solid tumors	1	19	48%	60%	50%
imatinib	gemcitabine	oxaliplatin	pancreatic cancer	1	27	50%	100%	67%
iniparib	carboplatin	gemcitabine	metastatic triple-negative breast cancer	2	61	37%	100%	38%
iniparib	carboplatin	paclitaxel	uterine carcinosarcoma	2	17	40%	100%	100%
lapatinib	gemcitabine	paclitaxel	breast cancer	1	13	56%	100%	91%
lapatinib	paclitaxel	trastuzumab	HER positive breast cancer	2	92	56%	100%	100%
lapatinib	paclitaxel	trastuzumab	HER2 positive breast cancer	3	171	42%	100%	100%
lapatinib	cytoxan	epirubicin	breast cancer	3	311	69%	100%	100%

lenvatinib	carboplatin	paclitaxel	non-small cell lung cancer	1	28	33%	100%	100%
lonafarnib	carboplatin	paclitaxel	ovarian cancer	2	53	100%	100%	100%
mapatumumab	carboplatin	paclitaxel	non-small cell lung cancer	2	73	100%	100%	100%
motesanib	carboplatin	paclitaxel	non-small cell lung cancer	1	23	100%	100%	100%
motesanib	carboplatin	paclitaxel	non-squamous non-small cell lung cancer	2	123	100%	100%	100%
motesanib	carboplatin	paclitaxel	non-squamous non-small-cell lung cancer	3	531	100%	100%	100%
motesanib	erlotinib	gemcitabine	solid tumors	1	34	100%	67%	100%
nintedanib	carboplatin	paclitaxel	gynceological malignancies	1	22	89%	100%	100%
obatoclox	carboplatin	etoposide	small cell lung cancer	1	25	54%	100%	100%
obinutuzumab	cytoxan	fludarabine	relapsed/refractory follicular lymphoma	1	28	80%	60%	80%
olaparib	cisplatin	gemcitabine	advanced solid tumors	1	23	1%	80%	56%
panitumumab	5-fluorouracil	cisplatin	recurrent or metastatic squamous-cell carcinoma of the head and neck	3	325	100%	100%	100%
panitumumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	2	154	100%	100%	100%
panitumumab	5-fluorouracil	irinotecan	metastatic colorectal cancer	3	591	100%	100%	100%
panitumumab	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	3	593	100%	100%	100%
panitumumab	capecitabine	oxaliplatin	colon cancer with liver metastases	2	49	100%	100%	80%
panitumumab	carboplatin	paclitaxel	advanced non-small cell lung cancer	2	131	42%	100%	100%
panitumumab	gemcitabine	irinotecan	cholangiocarcinoma	2	35	100%	100%	100%
panobinostat	carboplatin	paclitaxel	solid tumors	1	21	50%	100%	100%
pazopanib	5-fluorouracil	oxaliplatin	colorectal cancer	1	21	100%	100%	100%
pazopanib	capecitabine	oxaliplatin	colorectal cancer	1	29	100%	100%	68%
pazopanib	carboplatin	paclitaxel	solid tumors	1	34	25%	100%	100%
pertuzumab	carboplatin	gemcitabine	ovarian cancer	2	37	100%	100%	100%
pertuzumab	carboplatin	paclitaxel	ovarian cancer	2	37	100%	100%	100%
pertuzumab	docetaxel	trastuzumab	HER2 positive breast cancer	2	148	100%	100%	100%
pertuzumab	docetaxel	trastuzumab	metastatic breast cancer	3	397	100%	100%	100%
PF-3512676	carboplatin	paclitaxel	advanced non-small cell lung cancer	1	12	37%	100%	100%

PF-3512676	carboplatin	paclitaxel	advanced non-small cell lung cancer	3	383	37%	100%	100%
PF-3512676	cisplatin	gemcitabine	advanced non-small cell lung cancer	3	416	37%	100%	100%
pomalidomide	cisplatin	etoposide	extensive-stage small-cell lung cancer	1	22	89%	33%	100%
regorafenib	5-fluorouracil	oxaliplatin or irinotecan	colorectal cancer	2	45	67%	100%	100%
rituximab	bendamustine	lenalidomide	aggressive B cell lymphoma	1	14	25%	40%	70%
rituximab	cytoxan	flavopiridol	chronic lymphocytic leukemia	1	9	70%	25%	53%
rituximab	cytoxan	fludarabine	chronic lymphocytic leukemia	3	92	25%	64%	80%
rituximab	cytoxan	fludarabine	advanced indolent B-cell non-follicular lymphomas	2	46	25%	60%	80%
rituximab	cytoxan	fludarabine	chronic lymphocytic leukemia	3	82	33%	96%	80%
rituximab	cytoxan	fludarabine	chronic lymphocytic leukemia	3	408	33%	60%	80%
rituximab	cytoxan	fludarabine	chronic lymphocytic leukemia	3	276	33%	60%	45%
rituximab	cytoxan	pentostatin	chronic lymphocytic leukemia	3	92	33%	86%	25%
rituximab	epirubicin	fludarabine	chronic lymphocytic leukemia and prolymphocytic leukemia	2	44	33%	100%	50%
rituximab	fludarabine	mitoxantrone	follicular lymphoma	2	55	25%	60%	63%
rituximab	fludarabine	mitoxantrone	follicular or marginal zone lymphoma	2	18	25%	60%	75%
rituximab	fludarabine	mitoxantrone	recurrent or refractory rituximab naïve follicular non-Hodgkin's lymphoma	2	50	25%	60%	63%
rituximab	gemcitabine	oxaliplatin	diffuse large B-cell lymphoma	2	48	50%	83%	100%
sarcatinib	carboplatin	paclitaxel	advanced solid tumors	1	116	100%	100%	100%
semaxanib	cisplatin	irinotecan	advanced solid tumors	1	13	45%	40%	100%
sepantronium bromide	carboplatin	paclitaxel	non-small cell lung cancer	1 and 2	41	89%	100%	100%
sorafenib	5-fluorouracil	cisplatin	nasopharyngeal carcinoma	2	54	100%	100%	100%
sorafenib	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	2	97	100%	100%	100%
sorafenib	capecitabine	cisplatin	gastric cancer	1	21	100%	80%	64%
sorafenib	capecitabine	gemcitabine	advanced renal cell carcinoma	1	15	50%	75%	33%

sorafenib	capecitabine	gemcitabine	metastatic renal cell carcinoma	2	40	100%	100%	40%
sorafenib	capecitabine	oxaliplatin	pancreatic and biliary tract cancer	1	16	50%	100%	58%
sorafenib	carboplatin	paclitaxel	non-small cell lung cancer	1	13	43%	100%	100%
sorafenib	carboplatin	paclitaxel	non-small cell lung cancer	3	464	100%	100%	100%
sorafenib	carboplatin	paclitaxel	uveal melanoma	2	24	100%	100%	100%
sorafenib	carboplatin	paclitaxel	metastatic melanoma	3	393	86%	100%	100%
sorafenib	carboplatin	pemetrexed	solid tumors	1	20	50%	100%	100%
sorafenib	cisplatin	docetaxel	gastric and gastroesophageal junction adenocarcinoma	2	44	100%	100%	100%
sorafenib	cisplatin	gemcitabine	advanced biliary adenocarcinomas	2	37	50%	53%	89%
sorafenib	cisplatin	gemcitabine	advanced non-squamous non-small cell lung cancer	3	385	100%	100%	100%
sorafenib	cisplatin	gemcitabine	refractory solid tumors	1	19	100%	100%	100%
sorafenib	cisplatin	gemcitabine	pancreatic cancer	2	44	100%	100%	67%
sorafenib	cisplatin	S-1	gastric cancer	1	13	100%	90%	48%
sorafenib	cytarabine	idarubicin	acute myeloid leukemia	1 and 2	61	25%	100%	100%
sunitinib	5-fluorouracil	cisplatin	gastric cancer	1	34	50%	100%	80%
sunitinib	5-fluorouracil	irinotecan	colorectal cancer	2	71	75%	100%	100%
sunitinib	5-fluorouracil	irinotecan	colorectal cancer	3	386	75%	100%	100%
sunitinib	5-fluorouracil	irinotecan	metastatic colorectal cancer	1	37	75%	100%	100%
sunitinib	5-fluorouracil	oxaliplatin	advanced solid malignancies	1	53	75%	100%	100%
sunitinib	5-fluorouracil	oxaliplatin	colorectal cancer	1	12	75%	100%	100%
sunitinib	bevacizumab	paclitaxel	metastatic breast cancer	2	23	56%	100%	77%
sunitinib	capecitabine	cisplatin	advanced gastric cancer	1	28	50%	80%	100%
sunitinib	capecitabine	oxaliplatin	advanced gastric cancer	1	48	75%	64%	85%
sunitinib	carboplatin	paclitaxel	advanced solid tumors	1	43	50%	100%	100%
sunitinib	carboplatin	pemetrexed	advanced solid tumors	1	24	75%	100%	100%
sunitinib	cisplatin	gemcitabine	bladder cancer	2	36	75%	100%	100%
sunitinib	cisplatin	gemcitabine	bladder cancer	2	9	75%	80%	80%
sunitinib	cisplatin	gemcitabine	non-small cell lung cancer	1	28	75%	100%	100%
sunitinib	cisplatin	pemetrexed	non-small cell lung cancer and mesothelioma	1	31	75%	100%	100%

sunitinib	cisplatin	S-1	advanced or metastatic gastric cancer	1	27	38%	100%	60%
telatinib	capecitabine	irinotecan	advanced solid tumors	1	23	100%	80%	72%
temsirolimus	carboplatin	paclitaxel	advanced solid tumors	1	38	67%	100%	100%
temsirolimus	carboplatin	paclitaxel	squamous cell carcinoma of the head neck	1	18	67%	91%	57%
tigatuzumab	carboplatin	paclitaxel	non-small cell lung cancer	2	49	33%	100%	100%
tipifarnib	cytarabine	idarubicin	acute myeloid leukemia	1 and 2	82	75%	100%	100%
trastuzumab	5-fluorouracil	cisplatin	gastric and gastroesophageal junction cancer	3	38	100%	100%	95%
trastuzumab	bevacizumab	docetaxel	breast cancer	3	424	100%	100%	100%
trastuzumab	bevacizumab	lapatinib	metastatic breast cancer	1	26	100%	100%	69%
trastuzumab	bevacizumab	vinorelbine	HER2 positive breast cancer	2	29	100%	100%	100%
trastuzumab	capecitabine	cisplatin	gastric and gastroesophageal junction cancer	3	256	100%	100%	80%
trastuzumab	capecitabine	docetaxel	HER2 positive metastatic breast cancer	2	29	100%	100%	38%
trastuzumab	capecitabine	docetaxel	metastatic breast cancer	2	113	100%	100%	76%
trastuzumab	capecitabine	vinorelbine	breast cancer	2	50	100%	80%	67%
trastuzumab	capecitabine	vinorelbine	HER2 positive metastatic breast cancer	2	45	100%	68%	67%
trastuzumab	carboplatin	docetaxel	HER2 positive breast cancer	3	131	100%	100%	100%
trastuzumab	carboplatin	nab-paclitaxel	HER2 positive metastatic breast cancer	2	32	100%	33%	100%
trastuzumab	carboplatin	paclitaxel	aggressive HER2-positive breast cancers	2	29	100%	100%	100%
trastuzumab	carboplatin	paclitaxel	aggressive HER2-positive breast cancers	2	27	100%	100%	100%
trastuzumab	cisplatin	docetaxel	breast cancer	2	30	100%	100%	67%
trastuzumab	cytoxan	nab-paclitaxel	HER2 positive breast cancer	2	8	100%	89%	86%
trastuzumab	cytoxan	pegylated liposomal doxorubicin	HER2 positive metastatic breast cancer	2	48	100%	100%	64%
trastuzumab	cytoxan	docetaxel	breast cancer	2	493	100%	86%	100%

trastuzumab	cytoxan	epirubicin	breast cancer	3	309	100%	100%	100%
trastuzumab	cytoxan	epirubicin	HER2 positive metastatic breast cancer	2	69	100%	100%	86%
trastuzumab	docetaxel	gefitinib	metastatic breast cancer	1 and 2	31	100%	62%	100%
trastuzumab	docetaxel	non-pegylated liposomal doxorubicin	metastatic breast cancer	2	31	100%	100%	67%
trastuzumab	docetaxel	pertuzumab	HER2 positive breast cancer	2	107	100%	100%	100%
trastuzumab	docetaxel	vinorelbine	HER2 positive metastatic breast cancer	2	76	100%	100%	73%
trastuzumab	everolimus	vinorelbine	metastatic breast cancer	1	50	100%	50%	67%
trastuzumab	gemcitabine	paclitaxel	HER2 positive breast cancer	2	53	100%	100%	91%
trastuzumab	lapatinib	paclitaxel	HER2 positive breast cancer	2	109	100%	43%	100%
trastuzumab	neratinib	paclitaxel	HER2 positive breast cancer	1	21	100%	63%	100%
trasuzumab	docetaxel	lapatinib	HER2 positive breast cancer	1	53	100%	69%	100%
trebananib	5-fluorouracil	irinotecan	colorectal cancer	2	95	33%	100%	100%
trebananib	5-fluorouracil	oxaliplatin	advanced solid tumors	1	6	33%	100%	100%
trebananib	capecitabine	cisplatin	gastroesophageal cancer	2	171	33%	80%	80%
trebananib	carboplatin	paclitaxel	advanced solid tumors	1	7	33%	100%	100%
TSU-68	carboplatin	paclitaxel	non-small cell lung cancer	1	37	55%	100%	100%
TSU-68	cisplatin	S-1	advanced gastric cancer	2	45	100%	100%	48%
TSU-68	oxaliplatin	S-1	metastatic colorectal cancer	1	11	28%	100%	88%
vadimezan	carboplatin	paclitaxel	advanced non-small cell lung cancer	3	649	49%	100%	100%
vadimezan	carboplatin	paclitaxel	small-cell lung cancer	2	17	49%	100%	100%
vandetanib	capecitabine	oxaliplatin	metastatic colorectal cancer	1	9	100%	100%	100%
vandetanib	carboplatin	docetaxel	non-small cell lung cancer	2	158	100%	100%	100%
vandetanib	cisplatin	gemcitabine	non-small cell lung cancer	1	8	33%	100%	100%
vandetanib	cisplatin	vinorelbine	non-small cell lung cancer	1	9	33%	100%	67%
vandetanib	docetaxel	oxaliplatin	advanced gastroesophageal cancer	1	9	33%	100%	62%
vatalanib	5-fluorouracil	oxaliplatin	metastatic colon cancer	3	426	83%	100%	100%
vatalinib	5-fluorouracil	oxaliplatin	metastatic colorectal cancer	3	579	83%	100%	100%
volociximab	carboplatin	paclitaxel	non-small cell lung cancer	1	29	67%	100%	100%
vorinostat	azacitidine	gemtuzumab ozogamicin	acute myeloid leukemia	1 and 2	52	75%	33%	100%

vorinostat	capecitabine	cisplatin	advanced gastric cancer	1	30	67%	80%	80%
vorinostat	carboplatin	paclitaxel	advanced non-small cell lung cancer	2	62	67%	100%	100%
vorinostat	cytarabine	idarubicin	acute myeloid leukemia	2	75	60%	100%	100%
vorinostat	carboplatin	paclitaxel	advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer	2	18	25%	100%	100%
zibotentan	carboplatin	paclitaxel	advanced ovarian cancer	2	59	67%	100%	100%